Patent SG-11201900677S-A (SG)
Title: Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
Inventor: GRUPP STEPHAN
IPC: C12N5/0783
Filed: 2017-07-28
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIPO I PCT omit VIII °nolo III 110101110111001 oimIE (10) International Publication Number WO 2018/023025 Al (51) International Patent Classification: C07K 14/725 (2006.01) A61K 35/17 (2015.01) A61K 39/00 (2006.01) C12N 5/0783 (2010.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2017/044425 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/368,100 28 July 2016 (28.07.2016) US 62/455,547 06 February 2017 (06.02.2017) US 62/482,846 07 April 2017 (07.04.2017) US 62/514,542 02 June 2017 (02.06.2017) US (71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors; and (71) Applicants: ANAK, Oezlem [BE/FR]; c/o Novartis Phar- ma AG, 4002 Basel (CH). BILIC, Sanela [US/US]; 4711 153rd Ct, Urbandale, IA 50323 (US). BROGDON, Jen- nifer [US/US]; Novartis Institutes for Biomedical Re- search, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). CAMERON, John, Scott [US/US]; Novar- tis Institutes for Biomedical Research, Inc., 250 Massa- chusetts Avenue, Cambridge, MA 02139 (US). CHOU, William [US/US]; c/o Novartis Pharmaceuticals Corpora- tion, 1 Health Plaza, 315-3443, East Hanover, NJ 07936 (US). HOWARD, Danny, Roland, Jr. [US/US]; 38 Wool- ston Way, Washington, NJ 07882 (US). ISAACS, Randi [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). JUNE, Carl, H. [US/US]; 409 Baird Road, Merion Station, PA 19066 (US). LACEY, Simon [US/US]; 15 Brandy- wine Drive, Media, PA 19063 (US). MAUDE, Shannon [US/US]; 200 W Elm St., Suite 1215, Conshohocken, PA 19104 (US). MELENHORST, Jan, J. [US/US]; 11 Exton Circle, Cherry Hill, NJ 08003 (US). SHUSTER, Stephen [US/US]; 13 Forest Lane, Springfield, PA 19064-1005 (US). QUINTAS-CARDAMA, Alfonso [ES/CH]; 1408 Woodview Way, Apt. 1408, Malvern, PA 19355 (US). (74) Agent: COLLAZO, Diana, M. et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 11 N 1 O N 1 GO\" (54) Title: COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS ADN PD-1 INHIBITORS 0 (57) : Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of \" an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., 0 CD19, in combination with a PD-1 inhibitor.